Internal Medicine, Medical Oncology · Hackensack, NJ
NPI
1811958481
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
92 2nd St
Hackensack, NJ, 07601
Phone (551) 996-5087
Groups this clinician bills Medicare through
Medicare paid, 2024
$675K
60,211 services
Medicare patients, 2024
483
Average age 76
Drug cost, 2024
$2.0M
449 prescriptions
Company payments, 2025
$17K
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Harry D Harper was code Q5110 (injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram), 27,241 times for 25 patients. In total Harry D Harper billed 60,211 services in 81 codes, and Medicare paid $675K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-26.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 27,241 | 25 | $0.22 | $5,992 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 6,270 | 42 | $6.45 | $40K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,479 | 344 | $13.81 | $20K |
| 99215 Office E&M - Established | Office | 1,150 | 214 | $154.41 | $178K |
| 99214 Office E&M - Established | Office | 517 | 235 | $107.55 | $56K |
| Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 288 | 13 | $101.12 | $29K |
| 96372 Injection Administration | Office | 270 | 62 | $12.41 | $3,352 |
| 99232 Hospital E&M - Subsequent | Facility | 212 | 105 | $65.56 | $14K |
| 85025 Blood Count | Office | 137 | 21 | $7.61 | $1,043 |
| 80053 Clinical Chemistry | Office | 136 | 21 | $10.35 | $1,408 |
| 99233 Hospital E&M - Subsequent | Facility | 115 | 66 | $99.20 | $11K |
| 99223 Hospital E&M - Initial | Facility | 114 | 97 | $144.85 | $17K |
| 36415 Venipuncture Blood Collection | Office | 73 | 19 | $8.65 | $631 |
| 99205 Office E&M - New | Office | 36 | 36 | $190.80 | $6,869 |
| 99213 Office E&M - Established | Office | 20 | 14 | $79.48 | $1,590 |
By year: 2022 $443K for 49,599 services; 2023 $514K for 54,571 services; 2024 $675K for 60,211 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 137 | 21 | $7.61 | $1,043 |
| 80053 Clinical Chemistry | 136 | 21 | $10.35 | $1,408 |
| 36415 Venipuncture Blood Collection | 73 | 19 | $8.65 | $631 |
Medicare prescription drug claims, 2024
In 2024, the drug Harry D Harper prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 79 prescriptions and refills. In total Harry D Harper wrote 449 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 79 | 79 | 13 | $1.2M |
| Anastrozole Generic | 26 | 78 | Under 11 | $607 |
| Olanzapine Generic | 23 | 29 | 11 | $425 |
| Prednisone Generic | 23 | 23 | 13 | $71.56 |
| Ondansetron Hcl Generic | 21 | 21 | 13 | $98.54 |
| Duloxetine Hcl Generic | 16 | 16 | Under 11 | $126 |
| Warfarin Sodium Generic | 16 | 22 | Under 11 | $94.21 |
| Prochlorperazine Maleate Generic | 15 | 15 | Under 11 | $105 |
| Tepmetko Tepotinib Hcl | 12 | 12 | Under 11 | $279K |
| Imatinib Mesylate Generic | 12 | 12 | Under 11 | $2,202 |
| Lactulose Generic | 11 | 13 | Under 11 | $94.94 |
| Letrozole Generic | 11 | 25 | Under 11 | $239 |
Brand drugs: 149 claims; generic drugs: 300 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Harry D Harper $17K ($17K in general payments such as food, travel and fees) from 23 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $12K.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 15 | $12K |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $3,903 |
| Daiichi Sankyo Inc. 4568.T | 38 | $374 |
| Abbvie Inc. ABBV | 15 | $248 |
| Jazz Pharmaceuticals Inc. JAZZ | 5 | $203 |
| Janssen Biotech, Inc. JNJ | 5 | $164 |
| Merck Sharp & Dohme LLC MRK | 6 | $100 |
| Genentech USA, Inc. ROG.SW | 4 | $75.33 |
| PharmaEssentia USA Corporation 6446.TW | 4 | $72.28 |
| Agios Pharmaceuticals, Inc. AGIO | 3 | $52.23 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.